Amarin Corp Plcuk (AMRN) Net Income towards Common Stockholders (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Net Income towards Common Stockholders of -$10.5 million for Q1 2026, up 33.03% year-over-year from -$7.9 million in Q1 2025, and down 758.82% quarter-over-quarter from -$1.2 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$10.5 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$10.5 million, up 33.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$33.6 million (up 61.77% YoY), and the FY2025 annual result was -$38.8 million, up 52.79% from the prior year.
- Net Income towards Common Stockholders eased to -$10.5 million in Q1 2026 per AMRN's latest filing, from -$1.2 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $1.5 million in Q2 2024 and troughed at -$70.0 million in Q2 2022.
- A 5-year average of -$17.4 million and a median of -$14.1 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders slumped 1841.14% in 2022, then surged 108.67% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at $856000.0 in 2022, then slumped by 775.35% to -$5.8 million in 2023, then plunged by 741.0% to -$48.6 million in 2024, then soared by 97.48% to -$1.2 million in 2025, then sank by 758.82% to -$10.5 million in 2026.
- Business Quant data shows AMRN's Net Income towards Common Stockholders at -$10.5 million in Q1 2026, -$1.2 million in Q4 2025, and -$7.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.34 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | -10.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.51 Mn |
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -7.74 Mn |
| Jun 30, 2025 | -14.14 Mn |
| Mar 31, 2025 | -15.70 Mn |
| Dec 31, 2024 | -48.62 Mn |
| Sep 30, 2024 | -25.13 Mn |
| Jun 30, 2024 | 1.52 Mn |
| Mar 31, 2024 | -9.95 Mn |
| Dec 31, 2023 | -5.78 Mn |
| Sep 30, 2023 | -19.31 Mn |
| Jun 30, 2023 | -17.56 Mn |
| Mar 31, 2023 | -16.46 Mn |
| Dec 31, 2022 | 856,000.00 |
| Sep 30, 2022 | -5.14 Mn |
| Jun 30, 2022 | -69.96 Mn |
| Mar 31, 2022 | -31.56 Mn |
| Dec 31, 2021 | 14.70 Mn |
| Sep 30, 2021 | -13.15 Mn |
| Jun 30, 2021 | 7.81 Mn |